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Abstract
Androgens signal through the androgen receptor (AR) to regulate male secondary sexual
characteristics, reproductive tract development, prostate function, sperm production, bone
and muscle mass as well as body hair growth among other functions. We developed a
transgenic mouse model in which endogenous AR expression was replaced by a functional-
ly modified AR transgene. A bacterial artificial chromosome (BAC) was constructed contain-
ing all AR exons and introns plus 40 kb each of 5' and 3' regulatory sequence. Insertion of
an internal ribosome entry site and the EGFP gene 3’ to AR allowed co-expression of AR
and EGFP. Pronuclear injection of the BAC resulted in six founder mice that displayed
EGFP production in appropriate AR expressing tissues. The six founder mice were mated
into a Sertoli cell specific AR knockout (SCARKO) background in which spermatogenesis is
blocked at the meiosis stage of germ cell development. The AR-EGFP transgene was ex-
pressed in a cyclical manner similar to that of endogenous AR in Sertoli cells and fertility
was restored as offspring were produced in the absence of Sertoli cell AR. Thus, the AR-
EGFP transgene under the control of AR regulatory elements is capable of rescuing AR
function in a cell selective, AR-null background. These initial studies provide proof of princi-
ple that a strategy employing the AR-EGFP transgene can be used to understand AR func-
tions. Transgenic mice expressing selective modifications of the AR-EGFP transgene may
provide crucial information needed to elicit the molecular mechanisms by which AR acts in
the testis and other androgen responsive tissues.
Introduction
Androgens are a class of steroid hormones that regulate prostate function, bone density, cardi-
ac health, muscle mass, hair growth and fertility. Androgens diffuse through the plasma
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membrane and act via the intracellular androgen receptor (AR) to alter gene expression and in-
tracellular signaling pathways in target cells. The two major functional androgens in mammals
are testosterone and dihydrotestosterone (DHT). Because of the high levels of testosterone pro-
duced locally by the Leydig cells within the testis, this form of androgen is the major regulator
of testis functions and the male reproductive tract. In most other tissues, the lower concentra-
tions of testosterone present allow DHT to be the major acting androgen because DHT has a
10-fold greater affinity for AR than testosterone.
There are 2 two pathways by which androgens act to regulate cellular function. In the classi-
cal pathway, androgen interacts with AR in the cytoplasm that then translocates to the nucleus
where it binds androgen response element DNA sequences and directly regulates gene expres-
sion. In the non-classical pathway, androgens act via AR, in the cytoplasm, to rapidly activate
kinase cascades or alter intracellular [Ca2+] levels [1]. The resulting phosphorylation changes
alter the activities of target proteins that can cause immediate changes in cellular physiology as
well as indirect or delayed effects including altered gene expression. Non-classical AR action
has been documented in numerous cell types including skeletal muscle fibers [2], cardiac myo-
cytes [3], neurons [4], prostate cancer cells [5], macrophages and T-cells [6] as well as Sertoli
cells (reviewed in [7]).
In males, testosterone is essential for proper sexual differentiation and the maintenance of
spermatogenesis, which is the progression of germ cell development into mature sperm [8, 9].
Functional androgen receptor is not expressed in germ cells [10–12]. However, testosterone
support for germ cell development occurs via the Leydig, peritubular myoid cells and Sertoli
cells that express AR. Sertoli cells are the major transducers of testosterone signals to the adja-
cent germ cells. Assessments of spermatogenesis after testosterone deprivation studies and ex-
aminations of Sertoli cell specific AR knock out (SCARKO) mice have shown that testosterone
signaling through the AR in Sertoli cells is required to maintain the blood testis barrier [13, 14]
for the completion of meiosis (reviewed in [15]), maintaining the attachment of germ cells to
Sertoli cells and the release of mature spermatozoa [16–18].
The molecular mechanisms are beginning to be known by which androgen and AR regulate
processes in Sertoli cells that are required to maintain spermatogenesis. For example, there is
reduced expression of at least three tight junction components of the BTB (occludin, claudin
11 and claudin 3) in the absence of AR expression in Sertoli cells [13]. AR also is needed for the
recycling of BTB proteins during the remodeling of the BTB [19, 20]. Androgen suppression
disrupts two of the protein complexes that form the specialized connections (cadherin/cad-
herin and α6β1-integrin/lamininγ3) between Sertoli cells and the elongated spermatids [21,
22]. In the absence of androgen, there is an alteration in the phosphorylation of proteins in-
cluding focal adhesion kinase and β-catenin that decrease the integrity of the cadherin/cad-
herin and α6β1-integrin/lamininγ3intracellular connections leading to premature detachment
of elongated spermatids [21, 23].
Studies of SCARKOmice and testosterone depletion experiments have revealed specific
processes in Sertoli cells that require testosterone action. However, little information is avail-
able regarding the specific functions of classical versus non-classical androgen signaling in reg-
ulating critical spermatogenesis processes. An in vivomodel system in which endogenous AR
expression is replaced with specific AR mutants that selectively activate either the classical or
non-classical testosterone pathways would provide an essential tool for dissecting the molecu-
lar mechanisms by which AR acts. As a first step in achieving this goal, we produced transgenic
mouse strains that co-express AR and EGFP from a BAC insert containing the complete
mouse genomic AR gene and 40 kb each of 5’ and 3’ flanking sequences. The AR-EGFP trans-
gene is expressed in testosterone responsive tissues and is correctly expressed in AR positive
cells of the adult testis. Furthermore, we report the first transgenic rescue of AR function as the
Androgen Receptor Transgene
PLOS ONE | DOI:10.1371/journal.pone.0120783 March 24, 2015 2 / 19
Competing Interests: The authors have declared
that no competing interests exist.
AR-EGFP transgene is able to restore complete spermatogenesis and fertility in a SCARKO
mouse that lacks endogenous AR expression in Sertoli cells.
Materials and Methods
Ethics Statement
All mouse procedures were approved under protocol IS00000296 titled Nongenomic Androgen
Signaling in Sertoli Cells by the University of Pittsburgh Institutional Animal Care and Use
Committee (IACUC), which operates under protocol A3187-01 from the Association for As-
sessment and Accreditation of Laboratory Animal Care (AAALAC).
Construction of a BAC encompassing the AR genomic gene and 40 kb
each of 5’ and 3’ flanking regions
Three BACs containing all or parts of the gene encoding AR were obtained from the BACPAC
Resource Center (BPRC) at Children's Hospital Oakland Research Institute (CHORI, Oakland,
CA). One BAC [mAR BAC-192 (RP24-352D1)] contains the entire gene (all exons) for AR.
The other two BACs contain either 5’ [mAR BAC-185 (RP23-316P7)] or 3’ [mAR BAC-196
(RP23-102O11)] exons of the AR gene and either extensive 5’ or 3’ flanking regions (Fig. 1A).
The BACs containing the AR genomic sequence were end sequenced to establish the positions
of the inserts. Pulse field gel electrophoresis (PFGE) in combination with Southern blotting
was used to verify the inserts by comparisons of restriction analysis of the BACs with known
genomic sequence from the mouse genome project (Fig. 1B).
The mAR BAC-185 and mAR BAC-196 BACs, having the most extensive 5’ and 3’ se-
quences respectively of the three BACS, were linked together following techniques described by
Sopher et al. [24], using a targeting cassette constructed from a PCR product (S1 Fig.)
Fig 1. Characterization of three BACs containing parts of the AR gene. (A) Top: a map of the AR gene
and flanking region is shown. Below: maps of the BACs mAR BAC-196 (RP23-102011), mAR BAC-192
(RP24-352D1) and mAR BAC-185 (RP23-316P7) are shown. AR exons are denoted by rectangles on the
lines. SalI restiction sites are denoted with an S. Boxes above exons 1 and 8 denote the probes used for
Southern blotting. The BACs contained either extended 5’ sequence, the complete AR gene or extended 3’
sequence, respectively. The BACs were end sequenced to determine their insertion sites. (B) Restriction
digests followed by PFGE and Southern blotting were performed to ensure that preperations of the BACs
were correct. The SalI digested BACs were fractionated by PFGE and subjected to Southern blotting using
32P random primed labelled AR exon 1 and AR exon 8 probes. mAR BAC-192 was positive for both probes
while mAR BAC-196 only probed positive for exon 8 and mAR BAC-185 probed positive only for exon1.
doi:10.1371/journal.pone.0120783.g001
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containing 1176 bp of 3’ sequence from mAR BAC-196 (Fig. 2). The 1176 bp PCR product had
NotI and XbaI sites that were engineered into the primers so the amplicon could be direction-
ally subcloned into the multiple cloning site of pBluescript at NotI/XbaI (S1 Table.). A 1220 bp
cassette from pBluescript including the ampicillin resistance (ampr) gene was amplified using
PCR with primers that had AvrII/NotI and BamHI/EcoRI/ClaI sites added and inserted into
AvrII and ClaI sites of the targeting cassette replacing 383 bp of AR sequence between the
AvrII and ClaI sites. This process produced 598 bp and 276 bp homologous arms for recombi-
nation on both sides of the ampr cassette. Another 543 bp PCR fragment from the 3’ end of
mAR BAC-185 (S1 Table) was subcloned adjacent and 3’ to the ampr gene using the BamHI
and EcoRI restriction sites to yield the shuttle vector pAR2.6Amp (S1 Fig.). A SalI site was in-
troduced into the targeting cassette at the 3’ end of the fragment from mAR BAC-185 via a
PCR reaction. This Sal1 site was used later to release the recombined product from mAR BAC-
196.
The mAR BAC-196 was transformed into the SW102 strain of E. coli. This strain uses the
prophage λ exo, bet and gam gene products that are under temperature sensitive repression, to
perform homologous recombination. The insert from pAR2.6Amp was released using the NotI
and XbaI sites incorporated from pBluescript II SK- and this insert was transformed into the
SW102 strain containing mAR BAC-196 by electroporation and was grown at 42°C for 15 min.
to allow for recombination. Recombination was selected for using chloramphenicol/ampicillin
plates. DNA from recombined strains resistant to ampicillin was tested using PFGE and South-
ern blotting to ensure that the correct recombination had taken place and that there was no de-
letions, additions or rearrangements of the BAC.
The 3’ end of the recombined BAC (mAR BAC-196Amp, Fig. 2) was isolated using the in-
corporated SalI site and the endogenous SalI site located just 5’ of the recombination arm that
is common to both mAR BAC-196 and mAR BAC-185. The SalI fragment was isolated using
Fig 2. Construction of mARBAC-236. Portions of the BACs mAR BAC-185 and mAR BAC-196 were
combined to produce mAR BAC-236 that contained all AR exons and introns plus at least 40 kb each of 5’
and 3’ regions. (A) The targeting cassette derived from pAR2.6Amp (see S1 Fig.) was transformed into
SW102 cells that contained mAR BAC-196. (B) The recombination produced mAR BAC-196Amp where a
SalI site was introduced at the 3’ end just 3’ of a recombination arm common to both mAR BAC-185 and mAR
BAC-196. (C) The 3’ SalI fragment frommAR BAC-196Amp was isolated and transformed into SW102 cells
that contained mAR BAC-185. (D) Recombination of the 3’ SalI fragment with mAR BAC-185 added the
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PFGE to separate the smaller recombination cassette from the remainder of the BAC followed
by agarase digestion and dialysis on 0.05 μmVMWPmembranes (Millipore Corporation, Bil-
lerica, MA) floated on distilled water. The recombination cassette DNA was then electropo-
rated into SW102 cells containing mAR BAC-185 and recombined as above. The resulting
mAR BAC-236 (236 kb) was assessed using PFGE and Southern blotting to ensure correct
recombination occurred.
The final step of adding an IRES–EGFP cassette in the 3’ UTR just 3’ of the AR stop codon
was performed by inserting a GalK cassette into this position using the SW102 strain contain-
ing the mAR BAC-236 [25] (S2 Fig.). The GalK cassette was modified using primers having ho-
mology with the Galk cassette plus 50 bp overhangs (S2 Table) that are homologous to the
mAR 236-BAC insertion site. This PCR product was then transformed into the bacteria with
mAR BAC-236 and selected for in M63 minimal media where Galk is necessary for survival
(SW102 is GalK negative). A PCR product with the same 50 bp overhang (S2 Table) was used
to amplify the IRES-EGFP cassette that was transformed in the SW102 strain with mAR BAC-
236 (GalK). The correctly recombined BAC in which the IRES-EGFP cassette replaced the
Galk cassette was selected for using GalK counter selection plates containing 0.2% 2-deoxy-ga-
lactose (DOG). Galactose kinase phosphorylates 2-deoxy-galactose and produces a toxic prod-
uct (2-deoxy-galactose phosphate). The bacteria containing the final construct mAR BAC-
236E was grown in LB medium with chloramphenicol and the BAC was purified using a double
acetate extraction, followed by two rounds of CsCl gradient separation. The CsCl band was ex-
tracted with water saturated 1-butanol, ethanol precipitated and resuspended in TE buffer. The
resuspended DNA was dialyzed using 25 mmMillipore 0.05 μmVMWPmembranes (Milli-
pore) against injection buffer. The DNA was assessed by PFGE for purity and to ensure that
the DNA was not fragmented. The DNA was then sent to the Transgenic Core at University of
Texas Southwestern Medical Center for pronuclear injection. Concentrations of DNA injected
into the pronucleus were titrated to result in incorporation of low copy numbers of the
AR-EGFP transgene as determined previously by Dr. Robert Hammer (Director, UT South-
western, Transgenic Core). The resulting mAR-BAC-236E germ line transmitted transgenic
founder mice are available upon request and have been placed in storage at the Jackson Labora-
tory (Bar Harbor, Maine).
Animal care and use
Animals used in these studies were maintained and euthanized according to the principles and
procedures described in the NIH Guide for the Care and Use of Laboratory Animals. Mice
were housed in a temperature and humidity controlled facility with a 12 h light/dark cycle.
ARflox/flox mice were obtained from Guido Verhoeven [26]. AMHCre mice were purchased
from JAX mice (Jackson Laboratory, Bar Harbor, ME). Mice were sacrificed by CO2 asphyxia-
tion followed by cervical dislocation.
Genotyping
PCR genotyping of mouse tails was used to identify mice containing the AR-EGFP transgene
(3’EGFPfor and 3’EGFPrev primers, Table 1), Cre recombinase (CREfor, CRErev primers) and
the AR gene containing flox sites in the introns surrounding exon 2 (AR exon 2 locus for, AR
exon2 locus rev primers).
Preparation of whole cell extracts and western blotting
To prepare whole cell lysates, mouse tissues from decapsulated testes, epididymis, heart, liver,
kidney, muscle and brain were isolated and homogenized in enhanced lysis buffer (ELB,
Androgen Receptor Transgene
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250 mMNaCl, 0.1% NP40, 50 mMHepes, pH 7.0, 5 mM EDTA, 0.5 mM dithiothreitol) with a
protease inhibitor cocktail, rocked for 15 min at 4°C and then pelleted (12,000 x g 15 min) to
remove cell debris. Cell lysates were fractionated by SDS-PAGE, transferred to polyvinylidene
difluoride (PVDF) membranes, and incubated with polyclonal primary rabbit antibodies
EGFP, (Cell Signaling #2956) at 1:1000, followed by horseradish peroxidase (HRP)-conjugated
second antibody. The antigen-antibody complex was visualized with Millipore ImmobilonTM
Western Chemiluminescent HRP substrate (Millipore). Immunoreactive signals from western
blot films were scanned with an Epson 1600 Expressions scanner using Epson Scan software.
Analysis of testis morphology, EGFP and AR expression
Testes were isolated and weighed followed by fixation in Bouin’s solution or 4% paraformalde-
hyde and parrafifin embedded. For analysis of testis morphology, Bouins fixed tissue sections
(5 μm) were stained with a periodic acid-Schiff staining kit (Sigma, St. Louis, MO) followed by
staining with hematoxylin. For analysis of EGFP or AR expression, paraformaldehyde fixed
sections were probed with either primary goat antisera against GFP (Abcam Inc., Cambridge,
MA ab5450, 1:1000 dilution) or polyclonal primary rabbit antisera against AR (Santa Cruz Bio-
technology, Santa Cruz, CA AR C19, Sc-815, 1:1000 dilution). For EGFP imunodetection, bio-
tin conjugated mouse anti-goat secondary antisera (Vectastain Elite ABC kit, Vector
Laboratories, Burlingame, CA) was added and bound antibodies were detected as described by
the kit instructions using DAB staining solution. Slides were counterstained with hematoxylin.
For AR immunodetection, secondary donkey anti-rabbit antisera with conjugated cy3 fluor
was added followed by staining with DAP1(4',6-diamidino-2-phenylindole). A charged cou-
pled device (CCD) video camera system was used to capture images of tubule cross-sections.
Isolation of genomic DNA from tissue and qPCR assays to determine
transgene copy numbers
Genomic DNA was extracted from testis samples using the DNeasy Blood and Tissue kit (Qia-
gen Inc, Valencia CA) according to the manufacturer’s instructions with the following modifi-
cation: an additional 15 min incubation with RNase (10 mg/mL) was included after tissue
digestion in lysis buffer. DNA concentrations were obtained using spectrophotometric deter-
mination (OD260). Quantitative PCR (q-PCR) was performed on isolated testis genomic DNA
using the Applied Biosystems 7500 Fast Real-Time System (Life Technologies Carlsbad CA)
and SYBR Green PCRMaster Mix (Life Technologies Carlsbad CA). For each reaction, 100 ng
of genomic DNA and a final primer concentration of 250 nM each were used. Primers were de-
signed to obtain amplicons of 212 or 245 bp. A common forward primer (Common AR For1)
was used that anneals to the extreme 3’ end of the sequences flanking the AR gene that are pres-
ent on the X-chromosome and in BAC-236E (S3 Table). Two reverse primers were used. One
primer (Gen AR Rev1) anneals 212 bp downstream on the X chromosome, whereas the second






AR exon2 locus for 5’-AGCCTGTATACTCAGTTGGGG-3’
AR exon2 locus rev 5’-AATGCATCACATTAAGTTGATACC-3’
doi:10.1371/journal.pone.0120783.t001
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reverse primer (Trans AR Rev2) is located within the ampicillin cassette that is present only at
the 3’ end of BAC-236E. All reactions were 40 cycles using standard ABI cycling conditions
(initial 2 min at 50°C, 10 min at 95°C, and 40 cycles of 15 s denaturation at 95°C and 1 min an-
nealing and extension at 60°C). Mean Ct (cycle threshold) values were determined from tripli-
cate samples in two separate experiments.
Prior to performing copy number assessments, dilutions of genomic DNA from mice con-
taining endogenous AR sequences and BAC-236E were used to generate standard curves that
provided the amplification efficiencies for the amplicons derived from endogenous flanking
AR sequences and BAC-236E. The amplification efficiencies were found to be equivalent (with-
in 0.5%). For each transgenic mouse strain, the relative number of copies of endogenous AR se-
quences and BAC-236E derived sequences were determined from their respective Ct (cycle
threshold) using the EΔCt method, where E is the efficiency of the reaction and ΔCt = Ct (target
gene) − Ct (control gene) (see Bio-Rad user bulletin #5279 at http://www.bio-rad.com). Be-
cause the amplification efficiencies for the 2 PCR products are approximately equal, the num-
ber of copies of BAC sequences can be normalized to the number of copies of endogenous AR
sequences, which are present in one copy in the genome. The calculated copy numbers were re-
ported after rounding to the nearest whole number. This method of determining the copy
number requires small amounts of DNA and is found to be accurate for low (<10) transgene
copy numbers [27, 28].
Statistical analysis
Results were analyzed by ANOVA with Newman-Keuls PLSD at a 5% significance level utiliz-
ing GraphPad Prism 4.3 (GraphPad Software, San Diego, CA).
Results
Construction of a BAC Containing the AR and EGFP Genes Flanked by
40 kb Each of AR 5’ and 3’ Sequences
Two bacterial artificial chromosomes (BACs) containing overlapping regions of the AR gene
locus were recombined to create a new BAC denoted mAR BAC-236 that encompasses the en-
tire 167 kb of the genomic mouse AR gene plus 40 kb each of 5’ and 3’ flanking sequence
(Fig. 1). Specifically, the BACs mAR BAC-196 and mAR BAC-185 having the most extensive
AR 5’ and 3’ flanking sequences were recombined via the use of a targeting cassette (S1 Fig.). A
targeting cassette containing the 3’ end of mAR BAC-196 plus a region common to both BACs
was used to add an ampicillin resistance gene and a Sal1 restriction site to the 3’ end of mAR
BAC-196. A SalI fragment consisting of the region extending from the second intron of AR
through the 3’ end of mAR BAC-196 that included the targeting cassette was excised and re-
combined with mAR BAC-185 to produce mAR BAC-236 containing the entire AR gene plus
extended 5’ and 3’ flanking sequences (Fig. 2). To facilitate the identification of cells expressing
the AR transgene, a DNA cassette containing an internal ribosome entry site (IRES) allowing
the bicistronic expression of EGFP from the same mRNA transcript was placed 3’ to AR stop
codon in mAR BAC-236 to create mAR BAC-236E (S2 Fig.).
Creation of Founder Mice Expressing the AR-GFP Transgene
The mAR BAC-236E construct was used for pronuclear injection and 9 founder mice contain-
ing germ line transmitted mAR BAC-236E were obtained. Whole testis extracts were assessed
by western blot for expression of EGFP as a marker for expression of the mAR transgene.
Androgen Receptor Transgene
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These studies showed that six of the nine lines of transgenic mice expressed EGFP in the testis
(Fig. 3A). EGFP also was expressed in other tissues that are testosterone responsive (Fig. 3B).
The AR-GFP Transgene Compensates for the Loss of the Endogenous
AR Gene in Sertoli Cells
The mouse lines that expressed the AR-EGFP transgene were mated with mice expressing the
Cre recombinase driven by the Sertoli cell specific AMH promoter (AMH-Cre). The resulting
male double transgenic mice (AMH-Cre; AR-EGFP/AR+/y) were mated with female mice in
which either one or both alleles of AR had flox sites flanking exon 4 (ARflox mice, obtained
from Guido Verhoeven) [26]. Genotyping of the male offspring from these matings identified
mice having only floxed AR, or floxed AR plus the Cre recombinase that should eliminate AR
expression resulting in a SCARKO phenotype or the combination of floxed AR, Cre recombi-
nase plus the AR-EGFP transgene in addition to 6 other genotypes (Fig. 4A). Adult testis
weight (corrected for body weight) was used to determine the effect of each genotype. Mice
having endogenous AR expression plus either Cre recombinase or floxed AR had testis weights
similar to that of mice having no transgenes (wild type) (Fig. 4B). In contrast, testis weight was
reduced to 26% of wild type in SCARKOmice in which both AMH-Cre and floxed AR were
present. When the AR-GFP transgene was added to the SCARKO background, the transgene
was able to rescue the SCARKO phenotype with a mean increase of testis weight to 65% of wild
type for 6 founder strains. Incorporation of the AR-EGFP transgene alone, AR-EGFP transgene +
AMH-Cre or AR-EGFP transgene + floxed AR did not alter testis size relative to wild type.
Individual AR-EGFP founder transgenic mouse strains were investigated further to deter-
mine the extent of the rescue phenotype. The AR-EGFP transgene strain 2464 permitted com-
plete rescue of SCARKO mice with testis weights similar to that of its wild type siblings
(Fig. 4C). Strains 2462, 2457, 2461, 2460 and 2458 showed varying levels of rescue with mean
testis weights that were 78%, 68%, 63%, 50% and 35% of wild type, respectively. These data sug-
gest that the AR-EGFP transgene provided either complete or partial rescue of spermatogenesis
Fig 3. Expression of the AR-EGFP transgene in founder mice. A) Testis whole cell extracts from 6
founder mice having germ line transmission of the AR-GFP transgene and extracts from Cos7 cells infected
with an adenovirus expressing EGFP (AdEGFP) by western blot. B) Whole cell extracts from the 2460
founder strain containing the AR-EGFP transgene were assayed for EGFP expression by western blot.
doi:10.1371/journal.pone.0120783.g003
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Fig 4. The AR-EGFP transgene increases testis weights in rescuemice. A) Agarose gel analysis is
shown of PCR reactions used to genotype mice employed primers that identify the AR-EGFP transgene (tg),
the Cre recombinase (Cre) or floxed endogenous AR (AR flox) and the AR transgene (AR tg). Mouse strains
were identified that expressed no transgenes (wild type, wt), the Cre recombinase (Cre), a floxed AR gene (AR
flox) as well as SCARKO and rescuemice. Mice expressing the AR-EGFP transgene (tg), the transgene + Cre
(Tg + CRE) or the transgene in the presence of a floxed AR gene (Tg + AR flox) also were identified. The sizes of
DNAmarkers in base pairs (bp) are shown below each gel image. B) Testis weight/body weights are provided for
mice expressing the transgenes as described in A. C) The testis weight/body weight for the individual rescue
mouse strains are shown relative to the samewt and SCARKO values used in panel B. Values with different
lowercase letters differ significantly (P<0.05). Panel B, n = 6 to 39, panel C, n = 3 to 14).
doi:10.1371/journal.pone.0120783.g004
Androgen Receptor Transgene
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depending on the transgenic mouse strain. Expression of the AR-EGFP transgene in addition
to endogenous AR did not affect testis weight.
AR-GFP Transgene Expression in Sertoli Cells Matches That of
Endogenous AR
To confirm that the AR-EGFP transgene was expressed in the testes of the transgenic mice in a
cell-specific manner, adult testis tissue sections were probed for the expression of EGFP. In
mice containing the AR-EGFP transgene, EGFP immunoreactivity was observed throughout
the cytoplasm of Sertoli cells surrounding germ cells as well as in Leydig cells that are known to
produce AR (Fig. 5). Immunofluorescence studies of AR expression also were performed on
testis tissue sections from SCARKO, wild type and rescue mice. AR expression was not detected
in Sertoli cells of SCARKOmice, as expected (Fig. 6). The SCARKOmice also had smaller sem-
iniferous tubule diameters due to the lack of post meiotic germ cells. In wild type mice, AR
immunoreactivity was detected in Sertoli cell nuclei in a stage-specific manner such that AR ex-
pression was detected in stage V-VIII seminiferous tubule cross sections with stages VI and VII
having the most intense AR staining. Testes from rescue mice also displayed AR immunoreac-
tivity in Sertoli cell nuclei in a stage-specific fashion mirroring that of the wild type mice. AR
expression in peritubular cell and Leydig cell nuclei was similar for the SCARKO, wild type
and rescue mice.
The AR-GFP Transgene Restores Full Spermatogenesis to Testes
Lacking AR in Sertoli Cells
As shown previously [26, 29], histological analysis of testis cross sections revealed that the di-
ameters of seminiferous tubule cross sections were decreased and spermatogenesis was halted
at the pachytene spermatocyte stage of meiosis in SCARKOmice (Fig. 7). In contrast, the ex-
pression of the AR-EGFP transgene in a SCARKO background (rescue mice) restored full sper-
matogenesis in 5 of the 6 transgenic lines as shown by the presence of round and elongated
spermatids as well as mature spermatozoa poised to be released (Fig. 7 and Table 2). As shown
previously [30], spermatogenesis proceeded normally in control mice containing either Cre
recombinase (n = 7) or floxed endogenous AR (n = 8) only (data not shown). In agreement
with the assays of testis weight, expression of the AR-EGFP transgene from strain 2464 permit-
ted full spermatogenesis in nearly all seminiferous tubule cross sections (Fig. 7 and Table 2).
Strains 2462, 2457, 2460 and 2461 displayed complete spermatogenesis in more than 50% of
tubule cross-sections. Strain 2458 displayed partial spermatogenesis rescue allowing germ cells
to proceed to an early stage of elongated spermatid development in about 10% of seminiferous
tubules. The extent of spermatogenesis rescue (Table 2) and testis weight restoration (Fig. 4) in
the presence of the AR-EGFP transgene were not correlated with the number of transgene cop-
ies integrated into the genome, which ranged from 1 to 3 copies in each strain (Table 2). In the
rescued mice from the 5 strains that allowed completion of spermatogenesis, sperm were ob-
served in the epididymis (data not shown). Furthermore, fertility was restored by the AR-EGFP
transgene as the male rescue mice sired liters. Specifically, four male rescue mice derived from
the 2457 founder strain were mated with seven wild type females. Pups were produced in six of
eight matings with 3, 6, 8, 6, 3 and 10 pups per litter. These mice provide the first in vivomodel
in which an AR transgene is capable of rescuing AR function in a Sertoli cell specific AR null
background. These results prove that the mAR BAC-236E construct has sufficient regulatory
sequence to not only direct expression of AR in Sertoli cells in vivo but express AR in a stage
specific manner so that spermatogenesis and fertility can be restored.
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Fig 5. EGFP is expressed in the testes of mice containing the AR-EGFP transgene. Testis tissue
sections frommice containing the AR-GFP transgene (A, C) and a mouse lacking the transgene (B) were
probed with secondary antisera alone (A) or with antiserum against GFP and secondary antisera (B, C).
Strong EGFP immunoreactivity (brown stain) was observed only in testes containing the AR-GFP transgene
probed with EGFP antiserum (C). EGFP immunoreactivity was present in the cytoplasm of Sertoli cells
Androgen Receptor Transgene
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Discussion
We report the first transgenic rescue of AR function. We obtained 9 founder mice from our
pronuclear injections, of which 6, expressed EGFP from the AR-EGFP modified BAC trans-
gene. This number of successful founders suggest that the transgene is insulated from copy
number and position effects due to its size. Because the AR gene is required for fertility and is
hemizygous (present only on the X chromosome) in males, the crosses required to produce res-
cue mice in males were made more complex. Nevertheless, we found that expression of the
AR-EGFP transgene from 5 of the founders was capable of restoring spermatogenesis in
SCARKOmice that lack Sertoli cell-specific endogenous AR expression. The rescue of testis
size and sperm production varied for the 5 mouse strains. One founder strain was found to res-
cue testis size to normal levels and reestablished full spermatogenesis in nearly all seminiferous
tubule cross sections. Other strains were capable of restoring full spermatogenesis but not in all
tubules. The mechanisms responsible for the variable rescue of spermatogenesis are not yet un-
derstood. However, it is possible that the extent of rescued spermatogenesis may be related to
the expression levels of the AR-EGFP transgene and the capability of each mouse strain to ex-
press the transgene in Sertoli cells in a stage specific manner. In wild type rodents, AR is ex-
pressed at high levels during stages VI-VIII during the cycle of the seminiferous epithelium but
AR expression is difficult to detect during other stages [31]. Also, it is possible that transgene
positional effects in some of the strains may limit transgene expression or disrupt the stage-spe-
cific expression of AR. Unlike most cases of BAC transgenesis, where the size of gene flanking
regions is very large, the mARBAC-236 flanking regions were limited to about 40 kb each due
to the size of the AR gene encompassing most of the BAC. Nevertheless, the rescue of the
SCARKO phenotype such that complete spermatogenesis and sperm production are restored
after the introduction of the AR-GFP transgene indicates the transgene was successful in repli-
cating stage-specific AR expression supporting spermatogenesis.
The AR-EGFP transgene was able to restore male fertility in otherwise infertile SCARKO
mice as evidenced by the pups produced by the mating of mice derived from the 2457 founder
strain in the SCARKO background. However, pups were not produced in 2 of 8 matings and
small litter sizes were observed for two other matings. The lower fecundity of some of the mat-
ings may be explained by the intermediate rescue phenotype displayed by the 2457 strain that
displayed a testis size that was restored to only 68% of wild type. Follow up studies will include
evaluation of the 2464 line of rescue mice to assess the fertility of mice that had testis size and
spermatogenesis restored to wild type levels.
There have been no previous reports of transgenic animals that successfully express AR
using limited 5’ regulatory sequences. The use of larger transgenes for AR was first reported by
Sopher et al. in which a 450 kb YAC containing the 100 kb human AR gene was modified by
homologous recombination to add 100 CAG repeats to exon 1 of the human AR gene. This AR
transgene successfully recapitulated X-linked spinal and bulbar muscular atrophy (SBMA) in
mice [32]. This approach was repeated using a BAC in which the same group added 162 CAG
repeats to the human gene. For this construct, the two BACs were combined using a recombi-
nation strategy that employed antibiotic positive selection and the two-step recombineering
strategy that we emulated [24]. However, we then used a Galk negative selection pop in/pop
out strategy to insert an IRES.EGFP cassette [33].
including concentrations of EGFP in the Sertoli cell cytoplasm surrounding germ cells (arrows) and in the
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Fig 6. AR is expressed stage-specifically in Sertoli cells of rescuemice. Testis cross sections from
SCARKO, wild type and rescue mice were probed with antisera against AR. Long green arrows denote AR
immunostaining (red immunofluorescence) in peritubular cell nuclei. Short yellow arrows show AR
expression in Leydig cells. White arrowheads denote AR immunostaining in Sertoli cell nuclei. Stages of the




PLOS ONE | DOI:10.1371/journal.pone.0120783 March 24, 2015 13 / 19
Fig 7. Expression of the AR-EGFP transgene rescues full spermatogenesis in a SCARKO
background. Testes cross sections stained with PAS-Hematoxylin are shown for postnatal day 105 mouse
littermates (founder 2464) that express only Cre recombinase (Control), Cre recombinase in the presence of
a floxed AR gene (SCARKO), and a SCARKOmouse expressing the AR-EGFP transgene (Rescue).
Bars = 100 μm, magnification: 40x objective.
doi:10.1371/journal.pone.0120783.g007
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Further evidence that substantial 5’ regulatory sequences are required for correct AR expres-
sion was provided by Ye et al. [34]. These investigators produced a transgenic mouse using a
BAC (BAC-192, Fig. 1) having 15.2 kb of AR upstream sequence including all AR gene exons
and introns plus 10 kb of downstream sequence. The BAC also encoded either the LacZ/EGFP
or Luciferase gene regulated by promoters under the control of AR to assay AR expression
from the BAC. Using this construct, it was found that expression of the AR transgene was di-
rected to Sertoli cells in the testis and that the expression was strongest in stages VII and VIII,
which is characteristic of endogenous AR expression [31]. In comparison, our transgene con-
tained an additional 25 kb of 5’ upstream sequence and 30 kb of downstream sequence. The
BAC was injected as circular construct. Based on previous studies, we expect these constructs
to roll out in tandem copies such that at least one full-length copy of the transgene is incorpo-
rated into the genome with contiguous flanking sequences [35–37].
The importance of correct temporal and cell-specific expression of AR transgenes was
shown previously using a model in which expression of an AR transgene was driven by the Ser-
toli cell-specific Androgen Binding Protein (ABP) promoter in the presence of an intact endog-
enous AR gene [38]. In this transgenic model, testis size was reduced to 60% of normal. This
gain of function transgenic mouse was found to strongly express the AR transgene in Sertoli
cells at early stages of development in neonates. The use of the heterologous ABP promoter
caused elevated levels of AR in Sertoli cells prior the normal onset of AR expression, thus caus-
ing the immature Sertoli cells to cease proliferating and differentiate earlier during testicular
differentiation. The precocious expression of AR resulted in fewer Sertoli cells allowing fewer
germ cells to be supported. In contrast, we did not observe any alteration in testis size in mice
retaining endogenous AR expression plus the AR-EGFP transgene. This result suggests that
the expression of the AR-EGFP transgene does not initiate prior to endogenous AR expression
and thus does not interfere with normal Sertoli cell proliferation and developmental patterns.
Also, we did not observe any delay in the initiation of spermatogenesis (data not shown). Thus,
AR-EGFP transgene expression in Sertoli cells appears to initiate at approximately the same
developmental time point as endogenous AR, although assays of AR-EGFP transgene expres-
sion through development must be performed to confirm this idea.
In the adult testis, expression of the AR-EGFP transgene is confined to the seminiferous tu-
bule stages where endogenous AR is expressed. The restriction of AR-EGFP transgene expres-
sion to stage VI-VII Sertoli cells provides additional evidence that the transgene is expressed
under tight regulation in a manner similar to that of endogenous AR. This timing and proper
Table 2. Summary of spermatogenesis rescue by specific founder strains.
Line Transgene copy number Age at sacriﬁce (days) # of mice tested Rescue
2457 1 81–133 8 +++
2458 3 83–106 4 -
2460 3 86, 105 2 +++
2461 3 73–114 3 +++
2462 3 78–116 2 +++
2464 2 43–101 3 ++++
No spermatids present
+ A few elongated spermatids present
++ Complete spermatogenesis in >10% of tubule cross sections
+++ Complete spermatogenesis in >50% of tubule cross sections
++++ Complete spermatogenesis in >90% of tubule cross sections
doi:10.1371/journal.pone.0120783.t002
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regulation of AR expression in the transgenic rescue mice is likely due to the use of the exten-
sive genomic AR transgene and its intronic and associated 5’ and 3’ flanking regulatory regions
(40 kb each). The lack of any effect on testis size in the presence endogenous AR expression
plus the AR-EGFP transgene also suggests that expression of the AR-EGFP transgene is not af-
fected by copy number and may be under strict physiological feedback control due to the large
AR flanking regions that are associated with the AR-EGFP transgene. This proposed feedback
control of AR transgene expression may explain the similar levels of spermatogenesis rescue
that occur in the presence of 1 to 3 copies of the transgene. The proper expression profile of the
AR transgene in Sertoli cells suggests that the transgene mimics the endogenous AR gene in
other AR expressing tissues. To this end, the gross morphological structure of the Leydig cells
and peritubular cells of the testis appeared normal, which suggests again that AR-EGFP trans-
gene did not affect endogenous AR function in these cells. Finally, normal AR male mice with
the transgene were functionally fertile and did not show any abnormalities.
The purpose of producing this mouse model expressing the AR-EGFP transgene was to pro-
vide proof of principle that the functional domains of AR protein could be studied through in
vivomutational analysis in the context of androgen signaling in the testis. Using the strategy
that we have validated, additional transgenic mouse strains can be created in which endoge-
nous AR is replaced with mutated AR constructs that can selectively activate only the classical
or non-classical signaling pathway. In the future, these transgenic models could be used to
study the functions of each testosterone-mediated pathway that are required to maintain sper-
matogenesis. These transgenic mice also may allow the identification of molecular and cellular
mechanisms by which testosterone acts in Sertoli cells to maintain fertility and to facilitate the
design of therapies to cure specific defects in testosterone-mediated signaling that cause infer-
tility. Furthermore, transgenic mice incorporating the AR transgene or mutated versions of the
AR transgene could be used to test male contraceptive candidates based on the blocking of spe-
cific testosterone dependent processes during spermatogenesis. Finally, the AR transgene and
mutated derivatives may be used to study testosterone regulation of physiologically important
processes in other tissues including oocyte development, sexual differentiation, heart function,
muscle mass maintenance and prostate tumor progression.
Supporting Information
S1 Fig. Strategy used to construct the targeting cassette pAR2.6-AMP for the addition of
the 3’ flanking region of the AR gene onto mAR BAC-185. A 1176 bp NotI-XbaI fragment at
the 3' end of the mAR BAC-196 was amplified using PCR. A 383 bp AvrII-ClaI fragment was
removed by restriction digestion and a 1220 bp PCR product containing the ampr cassette with
flanking AvrII and Cla1 sites from pBluescript SK- was inserted into the 1176 bp fragment.
BamHI and EcoRI sites were introduced into the amp cassette PCR product. The recombina-
tion arm (denoted B, common to both mar BAC-196 and mar-185) was amplified by PCR and
inserted into the BamHI and EcoRI sites. The amplification of the recombination arm intro-
duced a SalI site into the cassette allowing the removal of the 3’ SalI fragment in a later step.
The final targeting cassette was named pAR2.6-Amp.
(PDF)
S2 Fig. Creation of the bicistroninc AR-IRES-EGFP transgene. The Galk cassette was ampli-
fied using primers with 50 bp overhangs that were homologous to regions within exon 8 of AR
This GalK cassette was selected for using minimal media plates containing galactose. The IRE-
S-EGFP cassette was amplified by PCR using primers having the same 50 bp overhangs. Selec-
tion for BACs in which the Galk cassette was replaced by the IRES-EGFP cassette was
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performed on 2 deoxy galactose (DOG) plates (negative selection for GalK).
(PDF)
S1 Table. Oligonucleotides used to amplify the 543 bp fragment used for recombineering
mAR BAC-185 to mAR BAC-196 to produce mAR BAC-236. All oligonucleotides are 5’ to
3’.
(PDF)
S2 Table. Oligonucleotides used to produce PCR products to introduce the GalK cassette
into a position immediately 3’ to the stop codon of AR in Exon 8. Underlined sequences are
GalK or IRES.EGFP specific whereas other sequences are AR specific. The GalK cassette was
then replaced with an IRES.EGFP cassette that did not have a PolyA sequence so that the
mRNA produced would use the polyadenylation signal of AR. This recombineering step pro-
duced mAR BAC-236E. All oligonucleotides are 5’ to 3’.
(PDF)
S3 Table. Primers used for qPCR copy number evaluation.
(PDF)
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